These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15984185)

  • 21. Tolcapone in elderly patients with Parkinson's disease: a prospective open-label multicenter non-interventional trial.
    Ebersbach G; Storch A
    Arch Gerontol Geriatr; 2009; 49(1):e40-4. PubMed ID: 18835049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Parkinson's disease drug is available.
    Mayo Clin Health Lett; 1998 Aug; 16(8):4. PubMed ID: 9702132
    [No Abstract]   [Full Text] [Related]  

  • 23. Cognitive improvement during Tolcapone treatment in Parkinson's disease.
    Gasparini M; Fabrizio E; Bonifati V; Meco G
    J Neural Transm (Vienna); 1997; 104(8-9):887-94. PubMed ID: 9451720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 25. Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
    Welsh MD; Dorflinger E; Chernik D; Waters C
    Mov Disord; 2000 May; 15(3):497-502. PubMed ID: 10830415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
    Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease.
    Lees AJ; Ratziu V; Tolosa E; Oertel WH
    J Neurol Neurosurg Psychiatry; 2007 Sep; 78(9):944-8. PubMed ID: 17098835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [COMT inhibition with tolcapone].
    Nervenarzt; 1996 Jul; 67(7 Suppl Comt-hemmu):1-8. PubMed ID: 9404535
    [No Abstract]   [Full Text] [Related]  

  • 31. Gait analysis in advanced Parkinson's disease--effect of levodopa and tolcapone.
    Shan DE; Lee SJ; Chao LY; Yeh SI
    Can J Neurol Sci; 2001 Feb; 28(1):70-5. PubMed ID: 11252300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolcapone in the management of Parkinson's disease.
    Leegwater-Kim J; Waters C
    Expert Opin Pharmacother; 2006 Nov; 7(16):2263-70. PubMed ID: 17059382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COMT inhibition in Parkinson's disease: rationale and clinical relevance.
    Deleu D
    Acta Neurol Belg; 2000 Mar; 100(1):5-7. PubMed ID: 10779856
    [No Abstract]   [Full Text] [Related]  

  • 34. Catechol-O-methyltransferase inhibitors: new options for Parkinson's disease.
    Leicht MJ; Mitchell SD
    S D J Med; 1999 Aug; 52(8):295-7. PubMed ID: 10453205
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study.
    Eggert K; Oertel WH; Lees AJ;
    Clin Neuropharmacol; 2014; 37(1):1-5. PubMed ID: 24434524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
    Nutt JG
    Lancet; 1998 Apr; 351(9111):1221-2. PubMed ID: 9643737
    [No Abstract]   [Full Text] [Related]  

  • 37. Kleptomania treated with tolcapone, a catechol-O-methyl-transferase (COMT) inhibitor.
    Grant JE
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):295-6. PubMed ID: 21062636
    [No Abstract]   [Full Text] [Related]  

  • 38. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
    Mov Disord; 1999 Jan; 14(1):38-44. PubMed ID: 9918342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COMT inhibitors: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S45-51. PubMed ID: 12211139
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.